SANTA CRUZ BIOTECHNOLOGY, INC.

IL-13 (32116.11): sc-57261



BACKGROUND

Interleukin-13, or IL-13, is a pleiotropic cytokine that exhibits 30% sequence identity with IL-4 and shares many of the same biological activities. Like IL-4, IL-13 affects monocytes, macrophages and B cells by upregulating the expression of CD23 and MHC proteins and downregulating the expression of CD14. Both IL-4 and IL-13 are secreted by activated T lymphocytes and are powerful regulators of inflammation. Both inhibit the secretion of proinflammatory cytokines and chemokines from activated monocytes and stimulate the expression of IgE on activated B cells. IL-13 contains five cysteine residues and multiple N-linked glycosylation sites and has been reported to inhibit the production of IL-2 in natural killer cells. IL-13 cDNA encodes a 131 amino acid precursor with a 20 amino acid signal peptide which is cleaved to generate a mature protein.

REFERENCES

- 1. Minty, A., et al. 1993. Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses. Nature 362: 248-250.
- 2. McKenzie, A., et al. 1994. Measurement of IL-13. In J. Coligamn, et al, eds., Current Protocols in Immunology. New York: John Wiley and Sons, Unit 6.18.
- 3. Zurawski, G., et al. 1994. Interleukin-13 elicits a subset of the activities of its close relative interleukin-4. Stem Cells 12: 169-174.
- 4. Abrams, J. 1995. Immunoenzymetric assay of mouse and human cytokines using NIP-labeled anti-cytokine antibodies. In J. Coligamn, et al, eds., Current Protocols in Immunology. New York: John Wiley and Sons, Unit 6.20.1.
- 5. Katz, Y., et al. 1995. IL-13 results in differential regulation of the complement proteins C3 and factor B in tumour necrosis factor (TNF)-stimulated fibroblasts. Clin. Exp. Immunol. 101: 150-156.
- 6. Cosentino, G., et al. 1995. IL-13 downregulates CD14 expression and TNF α secretion in normal human monocytes. J. Immunol. 155: 3145-3151.
- 7. de Vries, J.E., et al. 1995. Immunoregulatory properties of IL-13: its potential role in atopic disease. Int. Arch. Allergy Immunol. 106: 175-179.
- 8. Deleuran, B., et al. 1996. Interleukin-13 suppresses cytokine production and stimulates the production of 15-HETE in PBMC. A comparison between IL-4 and IL-13. Cytokine 7: 319-324.
- 9. Marietta, EV., et al. 1996. Modulation of expression of the anti-inflammatory cytokines interleukin-13 and interleukin-10 by interleukin-3. Eur. J. Immunol. 26: 49-56.

CHROMOSOMAL LOCATION

Genetic locus: IL13 (human) mapping to 5g31.1.

SOURCE

IL-13 (32116.11) is a mouse monoclonal antibody raised against full length IL-13 of human origin.

PRODUCT

Each vial contains 100 μ g lgG₁ in 1.0 ml of PBS with < 0.1% sodium azide and protein stabilizer.

APPLICATIONS

IL-13 (32116.11) is recommended for detection of IL-13 of human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

Suitable for use as control antibody for IL-13 siRNA (h): sc-39642, IL-13 shRNA Plasmid (h): sc-39642-SH and IL-13 shRNA (h) Lentiviral Particles: sc-39642-V.

Molecular Weight of IL-13: 13 kDa.

Positive Controls: human heart extract: sc-363763.

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.